A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy

HIV Medicine

Volumn 5, Issue 4, 2004, Pages 278-283

  Green, H ^a   Hay, Phillip ^b   Dunn, D T ^a   McCormack, S ^a  

^a Clinical Trials Unit   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Antirerovial therapy; HIV; Opportunistic infections; Pneumocystis carinii pneumonia; Prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; GANCICLOVIR; INDINAVIR; LAMIVUDINE; PENTAMIDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINITIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 4043080583     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00221.x     Document Type: Article

References (17)

1. Ledergerber B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. J Am Med Assoc 1999; 282: 2220-2226.
2. 6/l. AIDS 2001; 15: 1509-1515.
3. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European study groups. N Engl J Med 2001; 344: 168-174.
4. Lopez Bernaldo, de Quiros JC, Miro JM, Pena JM et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection Grupo Estudio del SIDA 04/98. N Engl J Med 2001; 344: 159-167.
5. Furrer H, Opravil M, Rossi M et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS 2001; 15: 501-507.
6. Mussini C, Pezzotti P, Antinori A et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 2003; 36: 645-651.
7. Kirk O, Reiss P, Uberti-Foppa C et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239-250.
8. Zeller V, Truffot C, Agher R et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34: 662-667.
9. Shafran SD, Mashinter LD, Phillips P et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002; 137: 734-737.
10. Furrer H, Telenti A, Rossi M, Ledergerber B. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2000; 14: 1409-1412.
11. ElSadr WM, Burman WJ, Grant LB et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342: 1085-1092.
12. Currier JS, Williams PL, Koletar SL et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133: 493-503.
13. Berenguer J, Gonzalez J, Pulido F et al. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 394-397.
14. Curi AL, Muralha A, Muralha L, Pavesio C. Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy. Br J Ophthalmol 2001; 85: 471-473.
15. Jouan M, Saves M, Tubiana R et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001; 15: 23-31.
16. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51: 1-52.
17. Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 2001; 33: 1901-1909.